

Special Issue

RNA Therapy in Cancer Treatment: From Design to Clinical Translation

Message from the Guest Editor

This Special Issue explores the rapidly evolving field of RNA oncology therapy, focusing on innovations in molecular design, delivery platforms, and preclinical-to-clinical translation. We welcome submissions on the development of mRNA vaccines, non-coding RNA modulators (e.g., miRNA, siRNA, circRNA), and innovative strategies to overcome tumor resistance and immune evasion. Topics of interest include the following: Novel RNA Therapies: mRNA vaccines targeting oncogenes or tumor suppressor genes, RNA interference, and antisense oligonucleotides. Delivery Systems: Lipid nanoparticles, polymer vectors, and viral vectors optimized for tumor targeting and bioavailability. Combination Therapy Regimens: Combining RNA therapy with immunotherapy, chemotherapy, or radiotherapy to enhance anti-tumor efficacy. Clinical Advances: Biomarker-based patient stratification, combination therapy trials, and long-term safety assessments. We welcome original research, reviews, and perspectives that connect RNA biology with clinical oncology, aiming to accelerate the application of precision RNA therapy in cancer treatment.

Guest Editor

Dr. Zhouxiao Li

Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Deadline for manuscript submissions

31 July 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/263232

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).